A prospective observational study of Induced Pluripoteint Stem Cell-derived Cardiac Spheres transplantation EXTENDed Follow-up

General Information

Clinical trials phase Long term follow up
Start date (estimated) 2022-04-01
End date (estimated) 2029-03-31
Clinical feature
Label heart failure
Link http://purl.obolibrary.org/obo/SYMP_0000292

Administrative Information

ICTRP weblink https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-UMIN000047335
Other study identifiers
Name UMIN000047335
Description UMIN Clinical Trials Registry (UMIN-CTR)
Source weblink https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000053954
Public contact
Email ykishino@keio.jp
Public email ykishino@keio.jp
First name Yoshikazu
Last name Kishino
Phone +81-3-5843-6702
City Tokyo
Address freetext Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo
Sponsors Keio University


Which differentiated cell type is used
Label cardiac muscle cell
Link http://purl.obolibrary.org/obo/CL_0000746
Description Cardiac muscle cells are striated muscle cells that are responsible for heart contraction. In mammals, the contractile fiber resembles those of skeletal muscle but are only one third as large in diameter, are richer in sarcoplasm, and contain centrally located instead of peripheral nuclei.; This class encompasses the muscle cells responsible for heart* contraction in both vertebrates and arthropods. The ultrastucture of a wide range of arthropod heart cells has been examined including spiders, horseshoe crabs, crustaceans (see Sherman, 1973 and refs therein) and insects (see Lehmacher et al (2012) and refs therein). According to these refs, the cells participating in heart contraction in all cases are transversely striated. Insects hearts additionally contain ostial cells, also transversely striated muscle cells, but which do not participate in heart contraction.


Recruitment Status Unknown Status
Comment recruitment status Pending (Subjects of the safety study of regenerative therapy with allogeneic induced pluripotent stem cell-derived cardiac spheres for severe heart failure (jRCTa032200189) approved by the Specified Certified Regenerative Medicine Committee.)
Estimated number of participants 3